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Objectives This study sought to describe the presentation, management, and outcomes of patients
presenting with angiographic deﬁnite stent thrombosis (ST) at coronary bifurcations.
Background The development of drug-eluting stents has made it increasingly feasible to treat
bifurcation lesions percutaneously. However, ST at coronary bifurcations may be associated with
greater mortality than ST elsewhere.
Methods We analyzed a multicenter California registry comprising all cases of angiographic deﬁnite
ST at 5 academic hospitals from 2005 to 2010. Stenting was deﬁned as occurring at a bifurcation if
the main vessel stent crossed a side branch 2.0 mm in diameter (provisional single-stent
approach), or if there was a prior 2-stent bifurcation approach.
Results Among 173 cases of angiographic deﬁnite ST, we identiﬁed 20 cases of ST at coronary
bifurcations. Nine of 20 bifurcation ST (45%) occurred with a stent present in both the parent and
branch vessel. Eight cases had thrombus present in both the parent and side branch vessels.
In-hospital mortality was much higher for subjects with bifurcation ST than ST at a nonbifurcation
site (20% vs. 2%, p  0.0001). During a median follow-up of 2.3 years, ST at a coronary bifurcation
was associated with increased long-term mortality (hazard ratio [HR]: 3.3, 95% conﬁdence interval
[CI]: 1.4 to 7.7, p  0.007) and a signiﬁcantly higher risk for major adverse cardiovascular events
(HR: 2.2, 95% CI: 1.04 to 4.8, p  0.04) relative to ST at a nonbifurcation site.
Conclusions ST at coronary bifurcations is associated with a higher in-hospital and long-term
mortality than ST at nonbifurcation lesions. (Stent Thrombus in Acute Coronary Syndromes;
NCT00931502) (J Am Coll Cardiol Intv 2012;5:57–63) © 2012 by the American College of
Cardiology Foundation
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58Stent thrombosis (ST) is a rare complication of percutane-
ous coronary intervention (PCI) but is associated with high
morbidity and mortality. Many factors may predispose the
development of ST, including procedural variables, patient
pre-disposition to thrombosis, and properties of the stent
(1). Although ST was initially reported to have an in-
hospital mortality exceeding 30%, recent studies have re-
ported lower but still significant short-term mortalities
ranging from 5% to 10% (2–8). Improved understanding of
the risk factors for immediate and long-term adverse outcomes
among subjects who develop ST might help with risk stratifi-
cation and management of these challenging cases (4).
The percutaneous treatment of bifurcation lesions with
bare-metal stents was limited due to the prohibitively high
restenosis rates. The availability of drug-eluting stents
(DES) with significantly lower restenosis rates has made it
possible to percutaneously treat many bifurcation lesions
that might otherwise require surgical bypass (9). However,
PCI at a coronary bifurcation is
associated with a small but in-
creased risk of ST, ranging from
1% to 3% at mean follow-up of
10 months in randomized stud-
ies of bifurcation stenting (10).
Bifurcation PCI may also be an
independent risk factor for de-
velopment of very late ST (11).
Furthermore, ST at coronary bi-
furcations may jeopardize a
greater territory of myocardium
at risk and potentially increase
the risk of adverse cardiovascular
outcomes (12). Therefore, we hy-
pothesized that patients with ST
at coronary bifurcations would
have higher mortality than pa-
tients who develop ST at nonbifurcation sites. To answer this
question, we compared presentations and outcomes among
patients in a multicenter California registry of patients who
presented with angiographic definite ST, and we stratified our
analysis based on the presence of ST at a coronary artery
bifurcation.
Methods
The University of California ST registry contains all con-
secutive cases of angiographically determined definite ST at
5 academic medical centers (University of California, Davis;
University of California, San Diego; San Francisco Veter-
an’s Administration Hospital; San Francisco General Hos-
pital; and University of California, San Francisco Moffitt-
Long Hospital) from 2005 to 2010 (8). Cases were
identified using cardiac catheterization laboratory records
Abbreviations
and Acronyms
CABG  coronary artery
bypass graft
CI  confidence interval
DES  drug-eluting stent(s)
HR  hazard ratio
MACE  major adverse
cardiac event(s)
PCI  percutaneous
coronary intervention
ST  stent thrombosis
STEMI  ST-segment
elevation myocardial
infarctionand, from 2008 onward, prospective enrollment of subjects.After identification of a potential ST, each case was re-
viewed for clinical and angiographic characteristics by 2
interventional cardiologists using the Academic Research
Consortium criteria for definite ST (13). Only cases of
angiographically determined definite ST were included in
the registry.
Once identified, definite ST cases were reviewed for
demographic, procedural, angiographic, and in-hospital
outcomes, as described previously (8). Briefly, trained ab-
stractors and physicians reviewed each medical chart for details
of presentation, medication compliance, and in-hospital out-
comes (death, stroke, or repeat myocardial infarction). Stent
thrombosis was defined as occurring “early” if the event
occurred 30 days after the index PCI; “late” if it occurred
1 month to 1 year after the index PCI; and “very late” if it
occurred1 year after index PCI. Long-term mortality was
assessed using hospital records, patient follow-up, and the
Social Security Death Index. Subjects were also prospec-
tively enrolled in a follow-up phone interview to assess for
the occurrence of repeat myocardial infarction, revascular-
ization, or stroke.
An interventional cardiologist blinded to outcomes re-
viewed the procedural details of each case, including loca-
tion of thrombus within the stent, whether thrombus was
present in the main and/or side branch vessels, TIMI
(Thrombolysis In Myocardial Infarction) flow grade, and
thrombus grading. Thrombus grading was angiographically
scored into 5 grades: 0 if there was no apparent thrombus;
1 if possible thrombus was seen; 2 if definite thrombus was
0.5 the vessel diameter; 3 if definite thrombus was 0.5 to 2
vessel diameters; 4 if definite thrombus was 2 vessel diame-
ers; and 5 if there was complete vessel occlusion from
hrombus (14). In cases where there was complete stent
cclusion by thrombus, thrombus grading was also recorded
fter initial lesion crossing with a wire but before balloon
nflation. A stent was defined as occurring at a bifurcation if the
ain vessel stent crossed a side branch 2.0 mm in diameter
designated a provisional single-stent approach) or if there were
stents present, with 1 originating in a main vessel and the
econd in a side branch (designated a 2-stent bifurcation
pproach).
Institutional review board approval was obtained at
ach site. Informed consent was obtained for prospec-
ively enrolled patients, whereas chart review was per-
ormed for retrospectively identified patients. Retrospec-
ively identified patients were also contacted to provide
nformed consent for a telephone interview. The trial has
een registered with identifier NCT00931502.
Statistical analyses. Median values with interquartile ranges
were used to describe continuous variables, and numerical
values (percentages) were used for categorical variables.
Univariate analysis was used to identify differences between
subjects with ST at bifurcation versus nonbifurcation sites.
Continuous variables were compared using the Kruskal-
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59Wallis test. Categorical values were compared by the chi-
square or Fisher exact test. Because most bifurcation ST
occurred at left anterior descending artery/diagonal branch
locations, a sensitivity analysis limited to ST of these vessels
was also performed. Long-term mortality was analyzed
using Kaplan-Meier survival analysis and log-rank test. A
Cox proportional hazards model was developed to explore
the relationship between bifurcation ST and risk of mortal-
ity and major adverse cardiac events (MACE). Known risk
factors for mortality (age, presentation with ST-segment
elevation myocardial infarction [STEMI], diabetes, chronic
kidney disease) were automatically included. Then, a list of
possible confounders was generated using a directed acyclic
graph. Confounders from this second group were retained if
they were found to be associated with the outcome, using a
p value 0.1 as a cutoff for inclusion. The final variables in
the model included age, sex, diabetes, history of chronic
kidney disease, prior coronary artery bypass graft (CABG),
type of thrombosed stent (DES or bare-metal stent), and
the involved vessel. The proportional hazards assumption
was verified using log-log plots. All analyses were performed
using Stata (version 11.0, STATA Corporation, College
Station, Texas). A p value0.05 was considered significant.
All authors had full access to and take full responsibility for
the integrity of the data. All authors have read and agree to
the manuscript as written.
Results
Among 173 cases of angiographically determined definite
ST, we identified 20 cases of angiographically determined
definite ST at coronary bifurcations, representing 12% of
cases in the registry. Compared with subjects with ST at
nonbifurcation locations (n  153), subjects with bifurca-
tion ST were younger (median: 57 vs. 61 years, p  0.03)
and were less likely to have previous CABG (0% vs. 15%,
p  0.07) or to be taking aspirin (58% vs. 78%, p  0.05)
or a thienopyridine (26% vs. 48%, p  0.08) at presentation
(Table 1). There was no difference in timing of ST between
groups, with most ST presenting very late regardless of
bifurcation status. Subjects with ST at a coronary bifurca-
tion were, however, more likely to have ST of a DES (80%
vs. 48%, p  0.02). There was a trend toward a higher risk
linical presentation among subjects with ST of a coronary
ifurcation, with a higher percentage of patients presenting
ith STEMI (80% vs. 64%) and with cardiogenic shock
25% vs. 20%).
The angiographic characteristics of patients with ST at a
oronary bifurcation are summarized in Table 2. Nine of 20
cases (45%) occurred at bifurcations with a stent present in
both the parent and branch vessel; the other 11 cases
occurred at a bifurcation with a single stent overlapping a
jailed side branch. Among subjects with thrombosis of 2
stents, the initial implantation technique was Culotte in 6 i(67%), simultaneous kissing stents in 1, and unknown in 2.
The pre-intervention TIMI flow grade was 0 in 70% of
cases. Most cases (55%) involved left anterior descending
artery/diagonal bifurcations, whereas the remainder con-
sisted of ST at circumflex/obtuse marginal bifurcations and
1 case of a left main ST. The majority (85%) of patients had
grade 4 or 5 thrombus within the stented region at the time
of initial angiography and before balloon inflation. The
thrombus originated in the proximal stented region in 16
(80%) cases. Eight of 20 (40%) cases had thrombus present
in both the parent and side branch vessels. Single-stent and
2-stent ST had a similar prevalence of thrombus extension
into the side branch (36% vs. 44%, pNS), suggesting that
the presence of a stent in the branch vessel was not
associated with increased thrombus burden. Intravascular
ultrasound was performed in 8 patients: this showed parent
vessel stent underexpansion in 3 cases and stent malappo-
sition in 2 cases. None of the cases had angiographic or
intravascular ultrasound evidence of residual dissection or
stent protrusion into the parent vessel.
Treatment of bifurcation ST included balloon angioplasty
of the target vessels and new stent implantation in at least 1
vessel in 17 of 20 cases. Consistent with a more acute
presentation, subjects with ST at a coronary bifurcation
were more frequently treated with aspiration thrombec-
tomy, heparin, glycoprotein IIb/IIIa antagonists, and intra-
aortic balloon counterpulsation (Table 1). All patients were
discharged on dual antiplatelet therapy.
In-hospital outcomes are summarized in Table 3. Proce-
dural success, defined as 30% residual stenosis with TIMI
flow grade 3 at the conclusion of the procedure, was 100%
in cases of ST at coronary bifurcations, as compared to 88%
in cases of ST at nonbifurcations (p  0.1). Despite high
procedural success, the peak creatine kinase and creatine
kinase-myocardial band levels were higher for subjects with
ST at bifurcation (median peak creatine kinase: 2,487 vs.
787 mg/dl, p  0.02), which is consistent with a large area
of myocardium at risk from the ST event. The rates of
referral for CABG were similar (5% vs. 6%, p  0.7).
n-hospital mortality was significantly increased for subjects
ith bifurcation ST (20% vs. 2%, p  0.0001). All in-
ospital deaths were due to heart failure. In-hospital mor-
ality remained significantly higher when the analysis was
imited only to ST of the left anterior descending artery/
iagonal territory (20% vs. 3%, p  0.03). Case mortality
as 33% for 2-stent bifurcations and 9% for single-stent
ifurcations (p  0.4). Two of the in-hospital deaths were
rom very late ST.
The Kaplan-Meier survival estimates for mortality and
ajor adverse cardiovascular events are shown in Figures 1
nd 2. During a median follow-up of 2.3 years, ST at a
oronary bifurcation was associated with increased long-
erm mortality (hazard ratio [HR]: 3.3, 95% confidence
nterval [CI]: 1.4 to 7.7, p  0.007). Bifurcation ST was
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60Table 1. Characteristics of Subjects With Angiographic Definite ST at Coronary Bifurcations
ST at Bifurcation
(n  20)
ST at Nonbifurcation
(n  153) p Value
Demographic characteristics
Age, yrs 57 (45–62) 61 (52–71) 0.03
Male 16 (80) 133 (87) 0.40
Prior CABG 0 (0) 22 (15) 0.07
Diabetes 7 (37) 59 (39) 0.80
Hypertension 16 (80) 118 (77) 0.80
Prior MI 14 (74) 105 (69) 0.70
Chronic kidney disease 1 (5) 22 (14) 0.20
Ejection fraction 45 (40–55) 50 (25–60) 0.30
Indication for initial stent implantation 0.30
Acute coronary syndrome 15 (75) 96 (63)
Stable angina 5 (25) 57 (37)
Timing of ST 0.60
Early 4 (20) 43 (30)
Late 4 (20) 22 (16)
Very late 12 (60) 76 (54)
Taking aspirin 11 (58) 114 (78) 0.05
Taking thienopyridine 5 (26) 70 (48) 0.08
Presentation 0.50
STEMI 16 (80) 97 (64)
NSTEMI 4 (20) 33 (22)
Unstable angina 0 (0) 16 (11)
Primary PCI 16 (80) 102 (67) 0.20
Cardiogenic shock 5 (25) 30 (20) 0.60
Type of thrombosed stent(s) 0.02
DES 16 (80) 72 (48)
BMS 1 (5) 40 (27)
Unknown 3 (15) 39 (26)
Angiographic details
Target vessel 0.02
LAD 12 (60) 70 (46)
RCA 0 46 (30)
Circumﬂex 7 (35) 25 (16)
Bypass graft 0 11 (7)
Target vessel location 0.20
Proximal 14 (70) 80 (54)
Mid-distal 6 (30) 68 (46)
TIMI ﬂow grade 3 16 (80) 140 (92) 0.10
Reference vessel diameter, mm 3.0 (2.5–3.2) 3.0 (2.6–3.5) 0.80
Procedural treatment
Thrombectomy 14 (70) 79 (52) 0.10
Balloon angioplasty alone 3 (15) 49 (33) 0.10
GP IIb/IIIa antagonist 18 (100) 114 (80) 0.04
Antithrombotic 0.05
Heparin 19 (95) 114 (76)
Bivalirudin 1 (5) 30 (20)
IABP 5 (25) 20 (14) 0.20
Values are median (interquartile range) or n (%).
BMS  bare-metal stent(s); CABG  coronary artery bypass graft; DES  drug-eluting stent(s); GP  glycoprotein; IABP  intra-aortic balloon
pump; LAD  left anterior descending artery; MI  myocardial infarction; NSTEMI  non– ST-segment elevation myocardial infarction; PCI 
percutaneous coronary intervention; RCA  right coronary artery; ST  stent thrombosis; STEMI  ST-segment elevation myocardial infarction;TIMI Thrombolysis In Myocardial Infarction.
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61also associated with a higher risk for MACE (HR: 2.2, 95%
CI: 1.04 to 4.8, p  0.04) relative to ST at a nonbifurcation
ite. MACE among patients with bifurcation ST included
ecurrent ST in 2 patients, which occurred 18 and 159 days
fter the initial ST. Both patients subsequently died during
eadmission for recurrent ST. Other MACE included 1
atient who required repeat target lesion revascularization
nd another who was referred for CABG.
After multivariable adjustment, including the type of
hrombosed stent and the involved vessel, bifurcation ST
emained associated with an increased risk of death and
ACE during long-term follow-up (adjusted HR for
eath: 6.7, 95% CI: 2.3 to 19.9, p 0.001; adjusted HR for
ACE: 3.7, 95% CI: 1.5 to 9.1, p  0.005).
Table 2. Angiographic Findings Among Subjects With ST at Coronary Bifur
Subject #
Timing
of ST
Bifurcation Technique
for Initial Stent
Implantation
Parent
Vessel
Side
Branch
Vessel
Pre
1 Early Culotte LAD Diagonal
2 Early Culotte Circumﬂex OM
3 Early Provisional Circumﬂex OM
4 Early Culotte LAD Diagonal
5 Late SKS LAD/left main Circumﬂex
6 Late Provisional LAD Diagonal
7 Late Culotte LAD Diagonal
8 Late Unknown—2 stents Circumﬂex OM
9 Late Provisional LAD Diagonal
10 Late Provisional Circumﬂex OM
11 Very late Unknown—2 stents LAD Diagonal
12 Very late Culotte LAD Diagonal
13 Very late Provisional LAD Diagonal
14 Very late Provisional Circumﬂex OM
15 Very late Provisional OM Circumﬂex
16 Very late Provisional LAD Diagonal
17 Very late Provisional Circumﬂex OM
18 Very late Provisional LAD Diagonal
19 Very late Provisional Diagonal LAD
20 Very late Culotte LAD Diagonal
Thrombus grade in parentheses represent TIMI thrombus grade after initial wire crossing in cases o
OM obtuse marginal; POBA balloon angioplasty only; SKS simultaneous kissing stent; oth
Table 3. In-Hospital Outcomes of Subjects With Coronary Bifurcation ST
Outcome
ST at Bifurcation
(n  20)
ST at Nonbifurcation
(n  153) p Value
Procedural success 20 (100) 130 (88) 0.10
Peak CK 2,487 (778–4,664) 787 (285–2,472) 0.02
Peak CK-MB 220 (84–300) 69 (25–233) 0.03
Referral for CABG 1 (5) 9 (6) 0.70
In-hospital mortality 4 (20) 3 (2.0) 0.0001
Values are n (%) or median (interquartile range).
CK  creatine kinase; CK-MB  creatine kinase-myocardial band; other abbreviations as inTables 1 and 2.iscussion
The major finding of this study is that angiographic ST at
a coronary bifurcation is associated with much higher
in-hospital and long-term mortality than angiographic ST
at nonbifurcation locations. This high mortality occurred
despite high rates of procedural and angiographic success,
s
vention
low
e
Thrombus
Grade
Location of
Thrombus
in Stent
Thrombus
in Both
Vessels Treatment of ST
5 (4) Proximal Yes Kissing balloon angioplasty
3 Mid No BMS to circumﬂex
5 (4) Proximal No DES to LAD and diagonal
5 (4) Proximal Yes Kissing balloon angioplasty
3 Mid No Kissing balloon angioplasty
4 Proximal No 2 DES to LAD; kissing POBA
to diagonal
5 (4) Proximal No DES to LAD
5 (4) Proximal No DES to circumﬂex and OM
5 (3) Proximal Yes DES to LAD
4 Proximal Yes DES to circumﬂex and OM
4 Proximal Yes DES to LAD and diagonal
1 Mid No DES to LAD; POBA to diagonal
4 Proximal No DES to LAD and diagonal
5 (4) Proximal Yes DES to circumﬂex; POBA to OM
4 Proximal No DES to OM
4 Proximal No BMS to LAD
5 (4) Proximal Yes DES to circumﬂex and OM
5 (3) Distal No 2 BMS to LAD
5 (4) Proximal No DES to diagonal; POBA to LAD
5 (4) Proximal Yes DES to diagonal; POBA to LAD
lete stent occlusion from thrombus.
eviations as in Table 1.
Figure 1. Long-Term Mortality of Subjects With Angiographic ST at
Coronary Bifurcations
Stent thrombosis (ST) at a coronary artery bifurcation was associated with a sta-cation
-Inter
TIMI F
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f comptistically signiﬁcant increased long-term mortality (p  0.004 by log-rank test).
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62emphasizing the importance of developing strategies to
prevent ST before it occurs at a coronary bifurcation.
Previous studies have consistently shown that stenting at
coronary bifurcations is associated with an increased risk of
subsequent ST (6,15,16). In a recent meta-analysis of 1-
versus 2-stent bifurcation techniques, the risk of ST was
similar regardless of technique (10). Most studies have
limited long-term follow-up; thus, the long-term risk of ST
at previously treated bifurcation lesions is unknown. Be-
cause our cohort included only cases of angiographically
determined definite ST, we cannot determine with certainty
the relative incidence of ST at bifurcation versus nonbifur-
cation sites, as the Academic Research Consortium defini-
tion of ST includes sudden death and subsequent autopsy
diagnosis. The mechanisms leading to an increased inci-
dence of ST in bifurcation stenting is also uncertain, but it
may be related to greater total stent length, impaired vessel
healing, or flow disturbance at the bifurcation (17,18). In an
autopsy series of bifurcation lesions, DES implantation was
associated with a greater number of uncovered stent struts
and fibrin deposition at the flow divider region versus at the
lateral walls (19). This observation suggests that impaired
vessel healing at the flow divider segment of a bifurcation
may be a nidus for initiation of platelet aggregation and
thrombus propagation.
Among studies that have examined outcomes after oc-
currence of an ST event, previously identified predictors of
subsequent adverse outcomes have included total stent
length, diabetes, depressed ejection fraction, and anatomi-
cally complex lesions (2,4). Bifurcation disease was not an
independent predictor of adverse events in these studies.
Our cohort differs in several characteristics, including a
Figure 2. Long-Term MACE of Subjects With Angiographic ST at
Coronary Bifurcations
Stent thrombosis (ST) at a coronary artery bifurcation was also associated
with a greater long-term risk of major adverse cardiac events (MACE)
(p  0.04 by log-rank test).higher prevalence of very late ST, which may explain thedifference in observed predictors of subsequent outcomes
after ST. Also, bifurcation lesions are by definition anatom-
ically complex and involve a longer total stent length than
nonbifurcation lesions do. Clinically, however, identifica-
tion of a bifurcation is more meaningful than measuring
total stent length or classification of a lesion based on
complexity.
Subjects with angiographic ST at coronary artery bifur-
cations had a high mortality despite angiographic and
procedural success. The high mortality was primarily due to
in-hospital death from heart failure, but also correlated with
continued risk of death and MACE at a median follow-up
of more than 2 years. This higher mortality is at least partly
explained by a larger area of myocardium at risk among
subjects with bifurcation ST, as the peak creatine kinase and
creatine kinase-myocardial band were higher among these
patients as compared to subjects with ST at nonbifurcation
sites. This suggests that, despite procedural success, patients
with bifurcation ST may be at higher risk of subsequent left
ventricular dysfunction. Additionally, the high prevalence of
thrombus in both the main and side branch vessel likely
resulted in greater distal embolization and microvascular
dysfunction. Consistent with this finding, higher thrombus
burden is associated with higher subsequent MACE, both
in de novo STEMI and after ST (20). Aspiration thrombec-
tomy and glycoprotein IIb/IIIa inhibitors were used with
increased frequency among patients with ST at coronary
bifurcations, but not in all cases. It is possible that more liberal
use of these adjunct agents to reduce thrombus burden could
improve outcomes in ST at coronary bifurcations.
In the absence of other specific therapies, prevention of
ST at coronary bifurcations remains paramount. Most
patients with ST at coronary bifurcations were not taking a
thienopyridine at the time of presentation. In fact, the rate
of antiplatelet medication (aspirin and/or thienopyridine)
usage was lower among subjects with ST at a bifurcation
than among the overall cohort of subjects with ST. Al-
though guidelines only require dual antiplatelet therapy for
1 year after stent implantation, the high mortality of
bifurcation ST may be a relative indication for continuing
dual antiplatelet therapy for more than 1 year in cases of
bifurcation stenting. Because a high proportion of patients
were not taking aspirin at presentation, it is possible that
compliance after treatment of bifurcation ST was also low,
thereby accounting at least in part for the higher rate of
MACE. Additional strategies to reduce the occurrence of
ST, such as administration of prasugrel in appropriate
patients, could also be considered (21).
Study limitations. This study should be interpreted in the
context of several limitations. First, the study population
included only cases of angiographically determined definite
ST. This may have resulted in selection bias, as patients that
did not live to hospital admission or who did not undergo
coronary angiography were not included in the cohort.
rC
1
1
1
1
1
1
1
1
1
1
2
2
J A C C : C A R D I O V A S C U L A R I N T E R V E N T I O N S , V O L . 5 , N O . 1 , 2 0 1 2 Armstrong et al.
J A N U A R Y 2 0 1 2 : 5 7 – 6 3 ST at Coronary Bifurcations
63Second, this study cannot make any statement about the
relative incidence of ST, as we identified patients at the time
of ST, rather than at the time of initial stent implantation.
Therefore, the increased prevalence of DES at bifurcations
does not necessarily reflect an increased risk of ST from
DES, but rather the preferential use of DES at bifurcation
lesions to prevent restenosis. Likewise, the high prevalence
of very late ST (50% in this study) reflects the population-
attributable risk of very late ST (i.e., more subjects at risk
who underwent PCI1 year prior as compared to1 year),
ather than an increased incidence of very late ST.
onclusions
Bifurcation ST is associated with significantly increased
in-hospital mortality compared to ST at nonbifurcation
sites despite aggressive intraprocedural anticoagulation and
mechanical support. Continued efforts to prevent ST will be
paramount to improving long-term outcomes of PCI at
coronary bifurcations.
Reprint requests and correspondence: Dr. Jason H. Rogers,
University of California, Davis Medical Center, 4860 Y Street, Suite
2820, Sacramento, California 95817. E-mail: jason.rogers@
ucdmc.ucdavis.edu.
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